# Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC

> **NIH NIH R01** · DUKE UNIVERSITY · 2020 · $653,173

## Abstract

ABSTRACT
A major problem facing both physicians and men with metastatic prostate cancer is predicting whether a
specific therapy will be effective. Currently, when a man develops metastatic castration resistant prostate
cancer, the initial therapy is frequently an inhibitor of androgen receptor activity such as enzalutamide or
abiraterone acetate. Following progression on hormonal therapies, taxane-based chemotherapy is frequently
employed. While these therapies improve overall survival and delay progression, there is great heterogeneity
between patients in the chances of clinical benefit, as defined by response rates and durations of responses.
While most men develop resistance to these second generation hormonal therapies within 1-2 years, some
men derive many years of benefit, while others do not respond or respond only transiently. Thus, an unmet
need is the ability to identify those men most likely to have durable benefits from these therapies, while sparing
those men unlikely to benefit the costs and toxicities associated with these agents. Predictive biomarkers
provide such an opportunity to optimize care delivery in this setting and reduce the heterogeneity of this
disease. In addition, such biomarkers will permit the design of novel approaches and clinical studies designed
to improve outcomes in those men in greatest need.

## Key facts

- **NIH application ID:** 10110161
- **Project number:** 1R01CA256157-01
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Andrew J Armstrong
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $653,173
- **Award type:** 1
- **Project period:** 2020-09-16 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10110161

## Citation

> US National Institutes of Health, RePORTER application 10110161, Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC (1R01CA256157-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10110161. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*